Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Alnylam Pharmaceuticals Cash Provided by (Used in) Financing Activity, Including Discontinued Operation increased by 103.5% to $15.71M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 65.9%, from $46.08M to $15.71M. Over 3 years (FY 2021 to FY 2024), Cash Provided by (Used in) Financing Activity, Including Discontinued Operation shows a downward trend with a -38.2% CAGR.
Analysis
How to read this metric
Negative values often indicate significant share buybacks or debt repayment, while positive values suggest new capital raising or increased borrowing.
Detailed definition
The total net cash flow resulting from all financing activities, including proceeds from debt issuance, share repurchase...
Peer comparison
Standard line item in the Statement of Cash Flows for all public companies.
other_net_cash_provided_by_used_in_financing_activitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $329.81M | $573.84M | $292.29M | $34.96M | $30.34M | $297.02M | $63.44M | $46.37M | $53.39M | $33.14M | $39.23M | $28.91M | $131.50M | $102.76M | $31.00M | $46.08M | $51.76M | -$448.35M | $15.71M |
| QoQ Change | — | +74.0% | -49.1% | -88.0% | -13.2% | +879.1% | -78.6% | -26.9% | +15.1% | -37.9% | +18.4% | -26.3% | +354.8% | -21.9% | -69.8% | +48.7% | +12.3% | -966.2% | +103.5% |
| YoY Change | — | — | — | — | -90.8% | -48.2% | -78.3% | +32.7% | +76.0% | -88.8% | -38.2% | -37.7% | +146.3% | +210.1% | -21.0% | +59.4% | -60.6% | -536.3% | -65.9% |
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
- Alnylam Pharmaceuticals (ALNY) reported cash provided by (used in) financing activity, including discontinued operation of $15.71M in Q1 2026.
- How has Alnylam Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Alnylam Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation decreased by 65.9% year-over-year, from $46.08M to $15.71M.
- What is the long-term trend for Alnylam Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation has grown at a -38.2% compound annual growth rate (CAGR), from $1.25B to $294.16M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- The net change in cash resulting from all financing-related activities.